OncoGenomX reports that 88.1% of 118 institutions could obtain PIK3CA analysis.
Published
Signal category
Research & Knowledge
Quote
“88.1% of 118 institutions could obtain PIK3CA analysis.”
— OncoGenomX team
Company
OncoGenomX
A Suisse start-up offering AI-enhanced oncology software to mitigate under-/overtreatment of women with breast cancer.
- Industry
- Embedded Software Products
- Location
- Allschwil, CH
- Company size
- 2 employees
On target is fine. On goal is everything. OncoGenomX is an ai-decision support solution (aiDSS) company known for its revolutionary approach to individualized drug-tumor matching, with the mission to end under- and overtreatment of patients, avoid expenditures for ineffective treatments, minimizing the risk of therapy failure and liability. Our software (PredictionStar) enables prescription of more than 20 different anti-cancer drugs – biologically targeted, goal oriented, evidence-based, and applicable, for certainty of therapy success before starting treatment. As the pioneers of biology-based drug-tumor matching and leader of reliable outcome prediction ahead of therapy start OncoGenomX is already a trusted name among breast cancer specialists. Working closely with oncologists, clinical researchers, international clinical study consortia and partner companies, OncogenomX is committed to game-changing software innovations - For optimal therapy of all tumors and all patients every time. For value-based cancer care, enabling longer, healthier, and better lives of people with cancer. Do you want to be a part of an innovation that redefines clinical decision support? We would love to hear from you and work together on creating an outcome and patient-oriented future. For more information we invite you to watch our video https://youtu.be/yyYcZYi3XTk, or to contact us directly at info@oncogenomx.ch.
Founded 2020